Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Travelan® Revenue Grows Significantly in US and Australia | |||||
By: Nasdaq / GlobeNewswire - 16 Feb 2018 | Back to overview list |
||||
Key Highlights:
MELBOURNE, Australia, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of many gut mediated diseases, is pleased to announce its half year sales results of its commercially available and over-the-counter gastrointestinal and digestive health supplement Travelan®. Travelan® experienced strong sales growth in both the U.S. and Australian markets throughout the first half of the 2018 financial year, reporting AU$335,000 in sales in the U.S. market, representing a 250% increase on the same period last year; and AU$579,000 in sales in the Australian market, representing a 27% increase on the same period last year. Immuron Marketing Manager Mr David Montgomery, said: “Key factors that have positively impacted the ongoing sales momentum include the continued focus on improving the execution of our trade marketing strategy in both the US and Australian markets. We are anticipating that the same sales trajectory will continue for Travelan® for the remainder of the 2018 financial year to target our aim of achieving in excess of AUD$2 million in annual sales for the first time”.
ABOUT IMMURON: FORWARD-LOOKING STATEMENTS: This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. |
|||||
|
|||||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |